Akron Biotech is supported by a team of world-class scientific and business advisors that provide expertise in areas of research and development relevant to our business. It is our goal to utilize our advisors to assist our company in staying competitive while achieving excellence . Collectively, our advisors comprise of respected leaders in the areas of business, scientific research and biotechnology industry. In addition, they have expertise is conducting business internationally in countries such as United States, Argentina, Europe and Israel. Our advisors are true pioneers in their respective fields, and they bring valuable scientific expertise to Akron and its ability to develop its technology. Through our Advisory Team, we are better prepared to identify and evaluate product opportunities, gain clinical advice, and enhance our relationships with the biotech industry worldwide. Our Advisory Team is comprised of:

Dr. Donny Strosberg

Dr. A. Donny Strosberg was trained as a Dr. Sci at the Free University of Brussels and did a post-doctoral fellowship at the Massachusetts General Hospital in Boston. After serving at Harvard Medical School as an Instructor and later as a Visiting Professor, he became Professor of Biochemistry and Immunology first in Brussels , then in Paris. With his teams he published over 370 peer-reviewed original scientific articles, several books and dozens of book chapters. He holds over twenty issued patents of which several were licensed to pharmaceutical companies. Prof. Strosberg is a co-founder of several biotechnology companies including Incyte listed on NASDAQ and Praecis founded with M.I.T and also listed on NASDAQ. He also helped run three bio-incubators for start-up enterprises. Prof. Strosberg was, between early 1999 and the end of 2004, the Chairman and CEO of Hybrigenics a company, which he founded in 1998, together with the Pasteur Institute. In March 2005, he was recruited as Professor of Infectology by The Scripps Research Institute for its Florida division to manage a program on Hepatitis C and Cancer, and help start new biotechnology companies in Florida, in association with the Institute. See also: www.donny-strosberg.com

Dr. J. Donald Capra

Dr. J. Donald Capra, M.D., President Emeritus, Oklahoma Medical Research Foundation, came to Oklahoma and OMRF in 1997 from the University of Texas Southwestern Medical Center in Dallas, Texas, where he served as professor of microbiology and internal medicine and was the Edwin L. Cox Distinguished Chair in Immunology and Genetics. He joined UT Southwestern in 1974 and in 1994 was named Director of Southwestern’s Molecular Immunology Center. A native of Vermont, Dr. Capra received his bachelor’s degree in chemistry and an M.D. from the University of Vermont. He held research fellowships at the National Institutes of Health and Rockefeller University, and was professor of microbiology at the Mount Sinai School of Medicine of the City University of New York prior to moving to Dallas. In his nine-year tenure as OMRF President, Dr. Capra oversaw an impressive period of growth and new scientific discovery. External research funding tripled, the scientific faculty grew from 36 to 49, and the number of graduate students at OMRF tripled. OMRF completed a five-year Capital and Endowment Campaign, exceeding its $100 million goal. Over 100,000 square feet of the OMRF facility was renovated, and the $15 million Donald W. Reynolds Center for Genetic Research and an administrative building and conference center were constructed. In May 2006, Dr. Capra stepped down as President of OMRF and currently holds the title of President Emeritus. He continues his research projects in the laboratory as Member and Head of the Molecular Immunogenetics Research Program at OMRF. Dr. Capra is well known for his studies of antibody genes and how they are mutated in autoimmune disorders. His early work on the relationship of the hypervariable regions of antibodies to the antibody combining site and idiotype of an immunoglobulin molecule are well known. He continues to do research on the immune system, especially the cells that produce antibodies and lymphomas, the tumors that arise from these cells.

David Gury

David Gury is the former Chairman and CEO of NABI Biopharmaceuticals. In May 1984, Mr. Gury joined NABI Biopharmaceuticals as President and Chief Operating Officer. He was elected Chairman of the Board, Chief Executive Officer and President in April 1992. During his tenure, the Company successfully transitioned from a plasma supplier into a fully integrated biopharmaceutical company. Prior to joining NABI Biopharmaceuticals, Mr. Gury spent his career with Abbott Laboratories in various administrative and executive positions and with Alpha Therapeutics Corporation, a spin out from Abbott. Mr. Gury completed his A.B. in economics at Kenyon College, Gambier, Ohio, in 1960 and received his MBA in Economics at the University of Chicago in 1962, specializing in accounting and finance. His undergraduate junior year was spent at the University of Madrid in Spain. He was a Research Fellow at the University of Chicago and an intern with Arthur Andersen & Co. He is also Chairman of the Board of Oragenics (AMEX), GeneEX(private) and Bioheart (Private). Mr. Gury is the Founding Chairman of the Florida Research Consortium; and past Chairman and a Founding Member of BioFlorida. Mr. Gury was an active developer of the biotechnology landscape in Florida thru active participation with the former Governor Bush and members of the State Legislature. He was appointed by Governor Bush to Scripps Florida Funding Corp. Board.

Dr. Ruth Arnon

Dr. Ruth Arnon is a member of the Israel Academy of Sciences and presently chairs its Science Division. Formerly Vice-President of the Weizmann Institute of Science (1988-1997), Professor Arnon is an internationally acclaimed immunologist. Prof. Arnon joined the Weizmann Institute in 1960. Prior to her appointment as Vice-President, she served as Head of the Department of Chemical Immunology and as Dean of the Faculty of Biology. From 1985 to 1994, Prof. Arnon was Director of the Institute's McArthur Center for Molecular Biology of Tropical Diseases. She has made significant contributions to the field of vaccine development, cancer research and the study of parasitic diseases. On the international scene, Prof. Arnon is an elected member of the European Molecular Biology Organization (EMBO). She has served as President of the European Federation of Immunological Societies (EFIS), Secretary-General of the International Union of Immunological Societies (IUIS). Prof. Arnon served from 1995 to 2001 as Chairman of the Science Division of the Israel Academy of Sciences and Humanities. Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology and the Israel Prize in Medicine 2001. Prof. Arnon has been also the Science Advisor to the President of Israel since 2001. Prof. Arnon, along with Prof. Michael Sela, conceptualized and developed Copaxone®, a multi-million dollar drug for the treatment of multiple sclerosis which was approved by the U.S. Food and Drug Administration and is presently marketed worldwide Prof. Arnon is the incumbent of the Paul Ehrlich Chair in Immunochemistry at the Weizmann Institute.

Dr. Fernando Alberto Goldbaum

Dr. Fernando Alberto Goldbaum began his career as a Biochemist in Buenos Aires, Argentina in 1986. In 1992, he obtained his Ph.D. in Biochemistry from the University of Buenos Aires. Dr. Goldbaum is a Researcher at Fundacion Instituto Leloir. From 1993 to 1997, he conducted postdoctoral training at the Center for Advanced Research in Biotechnology, University of Maryland, U.S., under the supervision of Dr. Roberto Poljak, in the fields of “Three-dimensional structure and Thermodynamic studies of antigen-antibody reactions” and” Molecular mimicry by anti-idiotypic antibodies”. Dr. Goldbaum has authored over fifty scientific articles, which have been published in major research journals and has several patent applications. He has been the recipient of a Howard Hughes Medical Institute International Fellowship since 2002 for his work on the “Relationship between molecular structure of protein antigens and their immunogenicity”.

Dr. Armando J. Parodi

Armando J. Parodi began his career as a Biochemist in Buenos Aires, Argentina in 1965. In 1970, he obtained his Ph.D. in Biochemistry from the University of Buenos Aires. Dr. Parodi has been a Researcher at the National Research Council (Argentina) since 1970. From 1982 to 1999, he was Professor of Biochemistry at the School of Sciences at the University of Buenos Aires; and from 1999 until 2003, he was a Professor of Cell Biology at the Institute for Biotechnological Research, University of San Martin (Argentina). From 1978 to 1990, he was a visiting Scientist at The Wellcome Research Laboratories, Research Triangle Park, North Carolina, U.S. and Research Associate at Duke University Medical Center, North Carolina, U.S. Dr. Parodi has conducted extensive research on Glycosylation of Proteins, mechanisms and pathways. He has authored over 100 scientific articles and chapters in eight books. He has been the recipient of an Eleanor Roosevelt International Union Against Cancer Fellowship, a John S. Guggenheim Memorial Foundation Fellowship, of the 1994 Award in Biology–The Third Academy of Science, Italy, and is currently a Howard Hughes Medical Institute International Research Scholar (1997-2011). Dr Parodi is a Foreign Associate of the National Academy of Sciences (USA) and a member of the American Academy of Microbiology. He was a member of the Advisory Committee on Pathogenesis and Functional Genomics, Special Program for Research and Training in Tropical Diseases, World Health Organization (1998-2005) and is or was a member of the Editorial Boards of Glycobiology (1991–1995; 2001–present), Molecular and Biochemical Parasitology (1987-2003), The FASEB Journal (1991-1999), and of the Journal of Biological Chemistry (2004-present).